Replimune Group, Inc. REPL
Replimune Group, Inc. (Nasdaq: REPL) is an oncology drug developer. Its lead program, TUDRIQEV (vusolimogene oderparepvec-wtpg), is in Phase 2 for Unresectable advanced cutaneous melanoma (anti-PD-1 failed). Its next catalyst on record is TUDRIQEV ARTACUS: Study report (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TUDRIQEV ARTACUS — Study report (2026). 7 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TUDRIQEV (vusolimogene oderparepvec-wtpg) | Unresectable advanced cutaneous melanoma (anti-PD-1 failed) | oncolytic virus (HSV-1) | Approved |
| TUDRIQEV | Non-melanoma skin cancers (CSCC, MCC, BCC, angiosarcoma) | oncolytic virus (HSV-1) | Phase 2 |
| TUDRIQEV (formerly RP1) | Skin cancers in solid organ transplant recipients (ARTACUS trial) | oncolytic virus (HSV-1) | Phase 2 |
| RP2 (sturlimgene erparepvec) | Metastatic uveal melanoma (ICI-naïve; REVEAL study) | oncolytic virus (HSV-1) with anti-CTLA-4 | Phase 2 |
| RP2 | Hepatocellular carcinoma (2L; with atezolizumab/bevacizumab) | oncolytic virus (HSV-1) with anti-CTLA-4 | Phase 1 |
| RP2 | Biliary tract cancer (with durvalumab) | oncolytic virus (HSV-1) with anti-CTLA-4 | Phase 1 |
| RP3 | Various solid tumors | oncolytic virus (HSV-1) with anti-CTLA-4, CD40L, 4-1BBL | Pre-clinical |
Recent results and decisions
- Oct 28, 2026started The global Phase 3 IGNYTE-3 confirmatory trial of TUDRIQEV in combination with nivolumab versus physician's choice in advanced melanoma is actively enrolling.
The global Phase 3 trial assessing TUDRIQEV in combination with nivolumab versus physician's choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment is actively enrolling.
Filing - Oct 28, 2026started The registration-directed Phase 2/3 REVEAL Study of RP2 in metastatic uveal melanoma is actively enrolling.
The registration-directed Phase 2/3 trial of RP2 in metastatic uveal melanoma is actively enrolling.
Filing - Oct 28, 2026started REVEAL registration-directed Phase 2/3 trial of RP2 in metastatic uveal melanoma is actively enrolling.
The trial is evaluating RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab.
Filing
9 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.